Shattuck Labs Inc
Company Profile
Business description
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Contact
500 W. 5th Street
Suite 1200
AustinTX78701
USAT: +1 512 900-4690
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
ASX data centre share forecasts AI fuelled earnings surge
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,301.85 | 32.65 | -0.39% |
| DAX 40 | 25,970.11 | 288.00 | -1.10% |
| Dow JONES (US) | 52,766.88 | 419.02 | -0.79% |
| FTSE 100 | 10,789.28 | 34.98 | -0.32% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,099.77 | 271.12 | -1.03% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,631.47 | 54.67 | -0.71% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |